Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bolt Biotherapeutics Inc (NQ: BOLT )

1.830 -0.020 (-1.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 187,881
Open 1.860
Bid (Size) 1.790 (5)
Ask (Size) 1.850 (5)
Prev. Close 1.850
Today's Range 1.800 - 1.910
52wk Range 1.180 - 2.720
Shares Outstanding 8,709,974
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
 
Via Benzinga

Performance

YTD
+33.58%
+33.58%
1 Month
+15.82%
+15.82%
3 Month
+15.09%
+15.09%
6 Month
+39.69%
+39.69%
1 Year
+7.65%
+7.65%

More News

Read More
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Looking Into Bolt Biotherapeutics's Return On Capital Employed
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies
Via Benzinga
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present at February Investor Conferences
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2022
Via Benzinga
SVB Leerink Cuts Price Target On This Stock By 50%, Also Check Out Some Other Major PT Changes
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Bolt Biotherapeutics's Return On Capital Employed Overview
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
7 Little-Known Penny Stocks That Could Take Off Any Moment
Via InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.